Spots Global Cancer Trial Database for Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
Official Title: A Prospective, Multicenter, Randomized, Open-label, Active Controlled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of Masitinib at 12 mg/kg/Day to Sunitinib at 50 mg/Day in Treatment of Patients With Gastro-intestinal Stromal Tumor Resistant to Imatinib
Study ID: NCT01506336
Conditions
Study Description
Brief Summary: The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institute Gustave Roussy (IGR), Villejuif, , France
Contact Details
Name: Axel Le Cesne, MD
Affiliation: Institut Gustave Roussy, Villejuif, France
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
